不同类别FAP放射性配体以延长肿瘤滞留时间的头对头比较:单体、二聚体、白蛋白结合剂和小分子与多肽的比较
该研究在体外和荷瘤小鼠中头对头比较了177Lu标记的FAPI-46单体与其二聚体、两种白蛋白结合剂偶联物及环肽FAP-2286。结果显示二聚化和环肽结构是延长肿瘤滞留时间、保护健康组织的 promising 策略,白蛋白结合策略效果取决于白蛋白结合部分,多肽在肿瘤/背景比方面有优势但肿瘤摄取依赖FAP表达。
要点
- 二聚体和环肽结构可延长肿瘤滞留时间并保护健康组织。
- 白蛋白结合策略的效果取决于所采用的白蛋白结合部分。
- FAP-2286在肿瘤/背景比方面有优势(除肿瘤/肾脏比外),但肿瘤摄取依赖FAP表达。
核心结论
- 研究提示二聚化和环肽结构是延长肿瘤滞留时间、保护健康组织的 promising 策略。
- 白蛋白结合策略的效果取决于白蛋白结合部分。
- 多肽在肿瘤/背景比方面有优势(肿瘤/肾脏比除外),但其肿瘤摄取依赖FAP表达。
研究设计与样本
- 体外评估了177Lu标记的配体在低表达(HT-1080.hFAP)和高表达(HEK-293.hFAP)人FAP的细胞系中的表现。
- 在HT-1080.hFAP和HEK-293.hFAP异种移植瘤中进行了SPECT/CT显像和生物分布研究。
- 估算了肿瘤摄取的曲线下面积(AUC)、肿瘤与关键器官比值以及吸收剂量。
主要发现
- 放射性配体的IC50在皮摩尔范围。
- 所有基于[177Lu]Lu-FAPI-46的放射性配体在两种肿瘤模型间摄取相似。
- [177Lu]Lu-FAP-2286在HEK-293.hFAP中摄取更高且背景最低。
- 在HT1080.hFAP异种移植瘤中,[177Lu]Lu-FAPI-46-F1D和两种白蛋白结合剂偶联物[177Lu]Lu-FAPI-46-Ibu与[177Lu]Lu-FAPI-46-EB的肿瘤摄取AUC和吸收剂量更高。
- 在HEK293.hFAP异种移植瘤中,[177Lu]Lu-FAPI-46-EB和[177Lu]Lu-FAP-2286的肿瘤摄取AUC和吸收剂量更高。
关键数值与推荐
- 肿瘤与关键器官的AUC值和吸收剂量有利于[177Lu]Lu-FAP-2286,但肿瘤/肾脏比除外。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Fibroblast activation protein-α (FAP)-targeting radioligands have recently demonstrated high diagnostic potential. However, their therapeutic value is impaired by the short tumor residence time. Several strategies have been tested to overcome this limitation, but a head-to-head comparison has never been done. With the aim to identify strengths and limitations of the suggested strategies, we compared the monomer FAPI-46 versus (a) its dimer (FAPI-46-F1D), (b) two albumin binders conjugates (FAPI-46-Ibu (ibuprofen) and FAPI-46-EB (Evans Blue)), and (c) cyclic peptide FAP-2286. METHODS: 177Lu-labeled ligands were evaluated in vitro in cell lines with low (HT-1080.hFAP) and high (HEK-293.hFAP) humanFAP expression. SPECT/CT imaging and biodistribution studies were conducted in HT-1080.hFAP and HEK-293.hFAP xenografts. The areas under the curve (AUC) of the tumor uptake and tumor-to-critical-organs ratios and the absorbed doses were estimated. RESULTS: Radioligands showed IC50 in the picomolar range. Striking differences were observed in vivo regarding tumor uptake, residence, specificity, and total body distribution. All [177Lu]Lu-FAPI-46-based radioligands showed similar uptake between the two tumor models. [177Lu]Lu-FAP-2286 showed higher uptake in HEK-293.hFAP and the least background. The AUC of the tumor uptake and absorbed dose was higher for [177Lu]Lu-FAPI-46-F1D and the two albumin binder conjugates, [177Lu]Lu-FAPI-46-Ibu and [177Lu]Lu-FAPI-46-EB, in HT1080.hFAP xenografts and for [177Lu]Lu-FAPI-46-EB and [177Lu]Lu-FAP-2286 in HEK293.hFAP xenografts. The tumor-to-critical-organs AUC values and the absorbed doses were in favor of [177Lu]Lu-FAP-2286, but tumor-to-kidneys. CONCLUSION: The study indicated dimerization and cyclic peptide structures as promising strategies for prolonging tumor residence time, sparing healthy tissues. Albumin binding strategy outcome depended on the albumin binding moiety. The peptide showed advantages in terms of tumor-to-background ratios, besides tumor-to-kidneys, but its tumor uptake was FAP expression-dependent.
引用
- Millul J, Koepke L, Haridas GR, et al. Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides. Eur J Nucl Med Mol Imaging. 2023. PMID: 37261473. doi:10.1007/s00259-023-06272-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。